# Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist

> **NCT03218969** · PHASE1,PHASE2 · COMPLETED · sponsor: **William Ondo, MD** · enrollment: 10 (actual)

## Conditions studied

- Restless Legs Syndrome
- Augmentation

## Interventions

- **DRUG:** Ecopipam
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03218969
- **Lead sponsor:** William Ondo, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2018-09-28
- **Final completion:** 2018-11-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03218969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03218969, "Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03218969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*